After Metformin, What Comes Next? Empagliflozin?After Metformin, What Comes Next? Empagliflozin?
Are we any closer to answering the question of what drug should be added when metformin monotherapy needs a boost? Two studies shed some light. Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 22, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology Viewpoint Source Type: news
The Year In Review: Type 2 Diabetes
(MedPage Today) -- Jardiance shows cardiovascular benefit; sugar under the spotlight (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 18, 2015 Category: Cardiology Source Type: news
Empagliflozin's CV Gains Explored in Diabetics With, Without HFEmpagliflozin's CV Gains Explored in Diabetics With, Without HF
Given the specter of associated heart failure with some antidiabetic medications, deeper analysis of the recently reported EMPA-REG OUTCOME trial of the SGLT2 inhibitor may reassure. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 17, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
Empagliflozin's CV Gains Seen in Diabetics With, Without HFEmpagliflozin's CV Gains Seen in Diabetics With, Without HF
Given the specter of associated heart failure with some antidiabetic medications, deeper analysis of the recently reported EMPA-REG OUTCOME trial of the SGLT2 inhibitor may reassure. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 16, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
Type-2 diabetes drug significantly reduces hospitalisations and deaths from heart failure
Findings from a large clinical trial known as EMPA-REG OUTCOME were reported at the American Heart Association annual conference; they demonstrate for the first time that a type-2 diabetes drug, Jardiance, reduces risk of heart failure.
EurekAlert (Source: Society for Endocrinology)
Source: Society for Endocrinology - November 11, 2015 Category: Endocrinology Source Type: news
How EMPA-REG Has Changed My PracticeHow EMPA-REG Has Changed My Practice
The EMPA-REG Outcomes trial found that the diabetes drug empagliflozin was not only safe but it actually provided cardiovascular benefits in high-risk patients. Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - November 9, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news
Lilly diabetes drug cuts heart failure death, hospitalization: study
ORLANDO (Reuters) - Eli Lilly's new diabetes drug Jardiance significantly cut the risk of heart-related death and hospitalization for heart failure in patients with type 2 diabetes who are at high risk for serious heart problems, according to data from a large study presented on Monday. (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 8, 2015 Category: Research Source Type: news
Heart Disease and Diabetes Trials Anticipated at Kidney WeekHeart Disease and Diabetes Trials Anticipated at Kidney Week
New data will be presented on empagliflozin in patients with diabetes, and results from trials of atorvastatin and kidney injury after cardiac surgery will be released. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 29, 2015 Category: Consumer Health News Tags: Nephrology News Source Type: news
September's top stories: GSK-Theravance COPD study, AstraZeneca cUTI results
GlaxoSmithKline (GSK) and Theravance reported the initial results of SUMMIT COPD survival study, AstraZeneca announced positive Phase III results of CAZ-AVI in patients with cUTI, and Boehringer and Lilly's diabetes drug Jardiance showed reduction in… (Source: Drug Development Technology)
Source: Drug Development Technology - October 7, 2015 Category: Pharmaceuticals Source Type: news
Sep 25 Cardiology News Sep 25 Cardiology News
The not-so-high risk of carotid artery occlusion, empagliflozin for type 2 DM, text messages for secondary prevention of heart disease, coffee and AF, ICD-10, and medical errors are the topics discussed by Dr John Mandrola in this week's podcast. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 25, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
Boehringer Igelheim aims for top slot with anti-diabetes drug launch
With Jardiance, BI has the advantage of significantly reducing cardiovascular risks associated with most patients with diabetes. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 24, 2015 Category: Pharmaceuticals Source Type: news
After EMPA-REG: Docs Dissect Diabetes Study, Discuss ImplicationsAfter EMPA-REG: Docs Dissect Diabetes Study, Discuss Implications
Doctors tried to make sense of the "unique" finding of the EMPA-REG OUTCOME study, which showed a mortality benefit for empagliflozin, but admitted the trial posed more questions than it answered. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 24, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Diabetes: Mulling Jardiance Heart Benefit
(MedPage Today) -- Results are "astounding," but what do they mean? (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 23, 2015 Category: Cardiology Source Type: news
Type 2 diabetes pill cuts risk of death
Drug company study says Jardiance is the first medication shown to lengthen diabetics' lives (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - September 18, 2015 Category: Consumer Health News Source Type: news
